Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe [Yahoo! Finance]
Alvotech (ALVO)
Company Research
Source: Yahoo! Finance
Advanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure successful market registration, commercialization, and patient access REYKJAVIK, Iceland and LONDON, June 18, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into an exclusive partnership agreement regarding the supply and commercialization of Alvotech's proposed biosimilar to Eylea ® (aflibercept). Alvotech is currently developing AVT06, a proposed biosimilar to Eylea ® low dose (2 mg) and AVT29, a biosimilar candidate for Eylea ® high dose (8 mg). Eylea ® is a widely used biologic for the treatment of eye disorders, including diseases which can lead to vision loss o
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® [Yahoo! Finance]Yahoo! Finance
- Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®GlobeNewswire
- Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewswire
- Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023) [Yahoo! Finance]Yahoo! Finance
- Alvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last week [Yahoo! Finance]Yahoo! Finance
ALVO
Earnings
- 5/21/24 - Miss
ALVO
Sec Filings
- 8/30/24 - Form EFFECT
- 8/29/24 - Form 424B3
- 8/21/24 - Form F-3
- ALVO's page on the SEC website